Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage

Bappaditya Ray, Vijay M. Pandav, Eleanor A. Mathews, David M. Thompson, Lance Ford, Lori K. Yearout, Bradley N. Bohnstedt, Shuchi Chaudhary, George L. Dale, Calin I. Prodan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high socio-economic burden. Prothrombotic states of early brain injury (EBI) and delayed cerebral ischemia (DCI) after aSAH determine morbidity and mortality. To understand how activated platelets might contribute to such prothrombotic states, we studied trends in coated-platelets during EBI and DCI periods. Serial blood samples from a prospective cohort of aSAH patients were collected and assayed for coated-platelet levels. Patient’s coated-platelet level during post-hospital discharge follow-up served as an estimate of baseline. Occurrence of DCI, Montreal cognitive assessment (MOCA) score of < 26, and modified Rankin scale (mRS) of 3–6 were considered poor clinical outcomes. Non-linear regression analysis detected a transition between periods of rising and declining coated-platelet levels at day 4. Additional regression analyses of coated-platelet trends before day 4 showed differences among patients with modified Fisher 3–4 [4.2% per day (95% CI 2.4, 6.1) vs. − 0.8% per day (95% CI − 3.4, 1.8); p = 0.0023] and those developing DCI [4.6% per day (95% CI 2.8, 6.5) vs. − 1.9% per day (95% CI − 4.5, 0.5); p < 0.001]. Differences between peak coated-platelet levels and baseline levels were larger, on average for those with DCI [18.1 ± 9.6 vs. 10.6 ± 8.0; p = 0.03], MOCA < 26 [17.0 ± 7.8 vs. 10.7 ± 7.4; p = 0.05] and mRS 3–6 [24.8 ± 10.5 vs. 11.9 ± 7.6; p = 0.01]. Coated-platelet trends after aSAH predict DCI and short-term clinical outcomes. The degree of rise in coated-platelets is also associated with adverse clinical outcomes.

Original languageEnglish (US)
Pages (from-to)459-470
Number of pages12
JournalTranslational Stroke Research
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Fingerprint

Subarachnoid Hemorrhage
Blood Platelets
Brain Ischemia
Brain Injuries
Regression Analysis
Economics
Morbidity
Mortality

Keywords

  • Acute brain injury
  • Hemorrhagic stroke
  • Hypercoagulability
  • Reactive platelets
  • Stroke morbidity

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Ray, B., Pandav, V. M., Mathews, E. A., Thompson, D. M., Ford, L., Yearout, L. K., ... Prodan, C. I. (2018). Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage. Translational Stroke Research, 9(5), 459-470. https://doi.org/10.1007/s12975-017-0594-7

Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage. / Ray, Bappaditya; Pandav, Vijay M.; Mathews, Eleanor A.; Thompson, David M.; Ford, Lance; Yearout, Lori K.; Bohnstedt, Bradley N.; Chaudhary, Shuchi; Dale, George L.; Prodan, Calin I.

In: Translational Stroke Research, Vol. 9, No. 5, 01.10.2018, p. 459-470.

Research output: Contribution to journalArticle

Ray, B, Pandav, VM, Mathews, EA, Thompson, DM, Ford, L, Yearout, LK, Bohnstedt, BN, Chaudhary, S, Dale, GL & Prodan, CI 2018, 'Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage', Translational Stroke Research, vol. 9, no. 5, pp. 459-470. https://doi.org/10.1007/s12975-017-0594-7
Ray, Bappaditya ; Pandav, Vijay M. ; Mathews, Eleanor A. ; Thompson, David M. ; Ford, Lance ; Yearout, Lori K. ; Bohnstedt, Bradley N. ; Chaudhary, Shuchi ; Dale, George L. ; Prodan, Calin I. / Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage. In: Translational Stroke Research. 2018 ; Vol. 9, No. 5. pp. 459-470.
@article{87911779614d47ba8639594b0180ce82,
title = "Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage",
abstract = "Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high socio-economic burden. Prothrombotic states of early brain injury (EBI) and delayed cerebral ischemia (DCI) after aSAH determine morbidity and mortality. To understand how activated platelets might contribute to such prothrombotic states, we studied trends in coated-platelets during EBI and DCI periods. Serial blood samples from a prospective cohort of aSAH patients were collected and assayed for coated-platelet levels. Patient’s coated-platelet level during post-hospital discharge follow-up served as an estimate of baseline. Occurrence of DCI, Montreal cognitive assessment (MOCA) score of < 26, and modified Rankin scale (mRS) of 3–6 were considered poor clinical outcomes. Non-linear regression analysis detected a transition between periods of rising and declining coated-platelet levels at day 4. Additional regression analyses of coated-platelet trends before day 4 showed differences among patients with modified Fisher 3–4 [4.2{\%} per day (95{\%} CI 2.4, 6.1) vs. − 0.8{\%} per day (95{\%} CI − 3.4, 1.8); p = 0.0023] and those developing DCI [4.6{\%} per day (95{\%} CI 2.8, 6.5) vs. − 1.9{\%} per day (95{\%} CI − 4.5, 0.5); p < 0.001]. Differences between peak coated-platelet levels and baseline levels were larger, on average for those with DCI [18.1 ± 9.6 vs. 10.6 ± 8.0; p = 0.03], MOCA < 26 [17.0 ± 7.8 vs. 10.7 ± 7.4; p = 0.05] and mRS 3–6 [24.8 ± 10.5 vs. 11.9 ± 7.6; p = 0.01]. Coated-platelet trends after aSAH predict DCI and short-term clinical outcomes. The degree of rise in coated-platelets is also associated with adverse clinical outcomes.",
keywords = "Acute brain injury, Hemorrhagic stroke, Hypercoagulability, Reactive platelets, Stroke morbidity",
author = "Bappaditya Ray and Pandav, {Vijay M.} and Mathews, {Eleanor A.} and Thompson, {David M.} and Lance Ford and Yearout, {Lori K.} and Bohnstedt, {Bradley N.} and Shuchi Chaudhary and Dale, {George L.} and Prodan, {Calin I.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s12975-017-0594-7",
language = "English (US)",
volume = "9",
pages = "459--470",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "5",

}

TY - JOUR

T1 - Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage

AU - Ray, Bappaditya

AU - Pandav, Vijay M.

AU - Mathews, Eleanor A.

AU - Thompson, David M.

AU - Ford, Lance

AU - Yearout, Lori K.

AU - Bohnstedt, Bradley N.

AU - Chaudhary, Shuchi

AU - Dale, George L.

AU - Prodan, Calin I.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high socio-economic burden. Prothrombotic states of early brain injury (EBI) and delayed cerebral ischemia (DCI) after aSAH determine morbidity and mortality. To understand how activated platelets might contribute to such prothrombotic states, we studied trends in coated-platelets during EBI and DCI periods. Serial blood samples from a prospective cohort of aSAH patients were collected and assayed for coated-platelet levels. Patient’s coated-platelet level during post-hospital discharge follow-up served as an estimate of baseline. Occurrence of DCI, Montreal cognitive assessment (MOCA) score of < 26, and modified Rankin scale (mRS) of 3–6 were considered poor clinical outcomes. Non-linear regression analysis detected a transition between periods of rising and declining coated-platelet levels at day 4. Additional regression analyses of coated-platelet trends before day 4 showed differences among patients with modified Fisher 3–4 [4.2% per day (95% CI 2.4, 6.1) vs. − 0.8% per day (95% CI − 3.4, 1.8); p = 0.0023] and those developing DCI [4.6% per day (95% CI 2.8, 6.5) vs. − 1.9% per day (95% CI − 4.5, 0.5); p < 0.001]. Differences between peak coated-platelet levels and baseline levels were larger, on average for those with DCI [18.1 ± 9.6 vs. 10.6 ± 8.0; p = 0.03], MOCA < 26 [17.0 ± 7.8 vs. 10.7 ± 7.4; p = 0.05] and mRS 3–6 [24.8 ± 10.5 vs. 11.9 ± 7.6; p = 0.01]. Coated-platelet trends after aSAH predict DCI and short-term clinical outcomes. The degree of rise in coated-platelets is also associated with adverse clinical outcomes.

AB - Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high socio-economic burden. Prothrombotic states of early brain injury (EBI) and delayed cerebral ischemia (DCI) after aSAH determine morbidity and mortality. To understand how activated platelets might contribute to such prothrombotic states, we studied trends in coated-platelets during EBI and DCI periods. Serial blood samples from a prospective cohort of aSAH patients were collected and assayed for coated-platelet levels. Patient’s coated-platelet level during post-hospital discharge follow-up served as an estimate of baseline. Occurrence of DCI, Montreal cognitive assessment (MOCA) score of < 26, and modified Rankin scale (mRS) of 3–6 were considered poor clinical outcomes. Non-linear regression analysis detected a transition between periods of rising and declining coated-platelet levels at day 4. Additional regression analyses of coated-platelet trends before day 4 showed differences among patients with modified Fisher 3–4 [4.2% per day (95% CI 2.4, 6.1) vs. − 0.8% per day (95% CI − 3.4, 1.8); p = 0.0023] and those developing DCI [4.6% per day (95% CI 2.8, 6.5) vs. − 1.9% per day (95% CI − 4.5, 0.5); p < 0.001]. Differences between peak coated-platelet levels and baseline levels were larger, on average for those with DCI [18.1 ± 9.6 vs. 10.6 ± 8.0; p = 0.03], MOCA < 26 [17.0 ± 7.8 vs. 10.7 ± 7.4; p = 0.05] and mRS 3–6 [24.8 ± 10.5 vs. 11.9 ± 7.6; p = 0.01]. Coated-platelet trends after aSAH predict DCI and short-term clinical outcomes. The degree of rise in coated-platelets is also associated with adverse clinical outcomes.

KW - Acute brain injury

KW - Hemorrhagic stroke

KW - Hypercoagulability

KW - Reactive platelets

KW - Stroke morbidity

UR - http://www.scopus.com/inward/record.url?scp=85037636328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037636328&partnerID=8YFLogxK

U2 - 10.1007/s12975-017-0594-7

DO - 10.1007/s12975-017-0594-7

M3 - Article

C2 - 29224114

AN - SCOPUS:85037636328

VL - 9

SP - 459

EP - 470

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 5

ER -